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Background and Objective. The role of adipokines in regulation of immune responses has been recognized, but very little is known
about their impact on multiple sclerosis (MS). In this study, we analysed whether the major adipokines are differentially expressed
in plasma of patients with different MS subtypes and clinically isolated syndrome (CIS) and explored their association with major
disease characteristics. Methods. The levels of adiponectin, adipsin, leptin, and resistin in the plasma of 80 patients with different
subtypes ofMS and CIS were followed up annually over the two years.The data obtained were correlated with disease activity, EDSS
and volumes of T1-weighted lesions (T1-LV), and fluid attenuation inversion recovery lesions (FLAIR-LV) on MRI. Results. In MS
group, a correlation was found between the level of adipsin and EDSS score at baseline (𝑟 = 0.506, 𝑝 < 0.001). In RRMS, the levels
of adipsin correlated with EDSS scores (𝑟 = 0.542, 𝑝 = 0.002), T1-LV (𝑟 = 0.410, 𝑝 = 0.034), and FLAIR-LV (𝑟 = 0.601, 𝑝 = 0.0001)
at baseline and an increase in the T1-LV over the follow-up (𝑟 = 0.582, 𝑝 = 0.003). Associations with other adipokines were not
detected. Conclusion. Our exploratory study provides novel insights on the impact of adipokines in MS and suggests that adipsin
exerts predictive potential as a biomarker of neurodegeneration.
1. Introduction
Multiple sclerosis (MS) is an autoimmune demyelinating
disease of the central nervous system (CNS) mediated by
the transendothelial migration of activated T helper 1 (Th1)
and Th17 lymphocytes into the brain tissue where they
trigger the destructive inflammatory cascade resulting in
the accumulation of inflammatory infiltrates, demyelination,
axonal loss, and gliosis [1, 2]. The damage to neural tissue
is induced by various effector mechanisms and substances
such as macrophage phagocytosis, secretion of inflammatory
cytokines, chemokines and antibodies, complement activa-
tion, mitochondrial dysfunction, release of cytotoxic pro-
teases, and products of oxidative stress and excitotoxicity that
all together contribute to the development of neurological
worsening [1].
Increased risk of MS in subjects with obesity during
adolescence and early adulthood has been recently reported
[3, 4]. It has been considered that such risk is explained
by modulatory effect of adipose tissue on inflammatory
responses in obese subjects. Indeed, adipose tissue is recog-
nized as an endocrine organ that secretes multiple cytokine-
like hormones, adipokines that are involved in regulation
of multiple physiological functions including inflammation
[5, 6]. Although dysregulation of adipokines during obesity
and in autoimmune diseases has been recognized, only
very little is known about their role in MS [5]. The best-
known adipokines are the proinflammatory leptin, adipsin,
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resistin and visfatin, and the anti-inflammatory adiponectin,
omentin-1, and apelin [5, 7]. Up to now, most studies in MS
have been focused on leptin that was found to be increased
in blood and cerebrospinal fluid (CSF) of MS patients, but
contrasting results have also been reported [8–11]. In these
studies, leptin correlated negatively with the number of
regulatory T cells [11], but associations to clinical parameters
were not reported. The levels of visfatin and resistin in sera
of MS patients were found to be increased, while the levels of
adiponectin were downregulated [9, 12–14]. Until now only
one study analysed several adipokines in a cohort of patients
including different subtypes of MS [14]. According to this
study, elevated levels of visfatin and decreased levels of leptin
were found in patients with relapsing-remitting MS (RRMS),
but association with clinical parameters was not detected.
Due to the sparse knowledge on the association of
adipokines with clinical characteristics of MS, the purpose
of this two-year prospective follow-up study was to assess
whether the levels of adiponectin, adipsin, leptin, and resistin
in plasma of MS patients are associated with clinical phe-
notypes, inflammatory disease activity, neurological disabil-
ity, and the volumes of T1-weighted and fluid attenuation
inversion recovery (FLAIR) lesions on magnetic resonance
imaging (MRI).
2. Patients and Methods
2.1. Subjects. This two-year prospective follow-up study
included altogether 80 subjects of whom 65 had clinically
definite MS (CDMS) according to the revised McDonald
Criteria [15] and 15 had clinically isolated syndrome (CIS)
[16]. The CDMS group included 34 patients with RRMS,
15 patients with secondary progressive MS (SPMS), and 16
subjects with primary progressive MS (PPMS). CIS patients
were defined as patientswhohadhad their first demyelinating
neurologic event suggestive of MS [16]. All patients under-
went annual neurological examinations from baseline up to
two years. The blood was drawn on the same day as the neu-
rological examination. The clinical evaluation included the
determination of body mass index (BMI, kg/m2), prestudy
disease activity (number of relapses two years before the
study), number of relapses over the two-year follow-up, and
Expanded Disability Status Scale (EDSS) score [17] at the
baseline and the end of the follow-up as summarized in
Table 1. Patients who were pregnant or suffering from any
other clinically significant diseases were excluded. The study
was approved by the Ethics Committee of TampereUniversity
Hospital and all subjects gave informed consent.
2.2. MRI Image Segmentation and Volumetric Analysis. All
patients underwent MRI examination at baseline and at
the end of follow-up period. All examinations were per-
formed on a 1.5 Tesla MRI Unit (Siemens Avanto, Erlan-
gen, Germany). The MRI protocol included a T1-weighted
header followed by axial T1-weightedmagnetization prepared
rapid gradient echo (MP-RAGE) and T2-weighted turbo
spin-echo (TSE), FLAIR, magnetization transfer contrasts
(MTC), diffusion weighted imaging (DWI), and gadolinium
enhanced T1-weighted MP-RAGE sequences. T1-weighted
MP-RAGE, FLAIR, and T2-weighted TSE images were used
for volumetric analysis. For MP-RAGE, the imaging param-
eters were as follows: repetition time (TR) = 1160ms; echo
time (TE) = 4.24ms; inversion time (TI) = 600ms; slice
thickness = 0.9mm; in-plane resolution = 0.45 ∗ 0.45mm.
In FLAIR images, the following parameters were used: TR =
8500ms; TE = 100ms; TI = 2500ms; slice thickness =
5.0mm; in-plane resolution = 0.45 ∗ 0.45mm. In TSE, the
following imaging scheme was used: TR = 750ms; TE =
115ms; slice thickness = 3.0mm; in-plane resolution = 0.90 ∗
0.90mm. Volumetric segmentation of plaques in the brain
was performed using semiautomatic software Anatomatic
operating in a PC/Window 95 environment [18, 19] and the
images were analysed blind.
2.3. Determination of Adipokines. Venous blood was col-
lected for the assessment of plasma levels of adiponectin,
adipsin, leptin, and resistin. Blood containing tubes were cen-
trifuged for 15min at 1600×g. Plasma was separated from the
blood, aliquoted, and stored at −70∘C until use. Adipokines
were determined by enzyme-linked immunoassay (ELISA)
using commercial reagents according to the manufacturers’
instructions (DuoSet ELISA, R&D Systems Europe Ltd.,
Abingdon, UK). The respective detection limits and interas-
say coefficients of variation were 15.6 ng/L and 2.0% for
adiponectin, 4.0 ng/mL and 3.8% for adipsin, 15.6 ng/L and
3.9% for leptin, and 15.6 ng/L and 4.0% for resistin.
2.4. Statistical Analysis. Statistical analyses were performed
with SPSS version 18.0 (SPSS Inc., Chicago, IL, USA). A 𝑝
value less than 0.05 was considered significant in all analyses.
Mann-Whitney 𝑈 test was used to analyse the differen-
ces in clinical parameters and MRI volumes between the
subtypes. Wilcoxon signed-rank test was used to analyse the
intraindividual changes in the volumes of MRI at each time
point.
For comparison of the adipokines levels in different
subtypes, repeated measures of ANOVA followed by Bon-
ferroni correction for multiple comparisons were used. For
each outcome, the analyses were also adjusted for age and
gender. Pearson’s correlation coefficient was used to explore
the relationship between the levels of adipokines with BMI or
age. The associations of adipsin levels with EDSS scores and
the volumes of T1-weighted and FLAIR lesions were studied
by linear regression model by adjusting for age, gender, and
disease subtype. Logistic regression model was used to study
the association between adipokines and disease activity. The
differences in the adipokines levels between genders were
studied by Mann-Whitney 𝑈 test.
3. Results
3.1. Clinical and MRI Follow-Up
3.1.1. Clinical Data. The demographic and two-year clinical
follow-up data of the subjects are summarized in Table 1. As
expected, the patients in the SPMS and PPMS groups had
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Table 1: Demographic and clinical characteristics of patients with different MS phenotypes.
RRMS
𝑛 = 34
SPMS
𝑛 = 15
PPMS
𝑛 = 16
CIS
𝑛 = 15
Gender F/Ma 24/10 10/5 9/7 13/2
Age (years)b 37.6 ± 9.2(20–51)
49.3 ± 10.0
(32–63)
58.1 ± 8.5
(40–70)
35.6 ± 7.9
(24–51)
BMI (kg/m2)b 24.9 ± 4.0(19.7–35.4)
26.2 ± 5.0
(15.8–33.3)
24.6 ± 3.4
(19.8–31.5)
25.3 ± 3.2
(21.6–31.2)
Disease duration from first symptoms (years)b 8.2 ± 7.2(0.7–29.6)
19.8 ± 7.8
(6.3–34.3)
18.9 ± 9.6
(2.4–43.0)
3.0 ± 2.5
(0.5–8.9)
Disease duration from diagnosis (years)b 4.2 ± 4.1(0.0–13.7)
12.9 ± 9.0
(2.2–32.4)
13.1 ± 8.4
(1.5–27.2) NA
EDSS at baselineb 1.4 ± 1.5(0.0–6.0)
5.2 ± 1.6
(2.5–7.5)
4.7 ± 2.2
(1.0–7.0)
0.1 ± 0.3
(0.0–1.0)
EDSS at end of the follow-upb 1.5 ± 1.6(0.0–6.0)
5.5 ± 1.6
(2.5–8.0)
4.8 ± 2.1
(1.5–7.0)
0.1 ± 0.4
(0.0–1.0)
EDSS worsening during follow-upc 7 (21%) 6 (40%) 4 (25%) 1 (7%)
Prestudy disease activityb,d 1.2 ± 1.4(0–5)
0.2 ± 0.6
(0–2)
0.0 ± 0.0
(0-0)
0.7 ± 0.6
(0–2)
Number of relapses over the follow-upb 0.6 ± 1.1(0–5)
0.4 ± 0.7
(0–2)
0.0 ± 0.0
(0-0)
0.1 ± 0.3
(0-1)
Treatment (NT/IFN/CO/MX)a 12/18/3/1 15/0/0/0 16/0/0/0 15/0/0/0
RRMS: relapsing-remitting MS, SPMS: secondary progressive MS, PPMS: primary progressive MS, CIS: clinically isolated syndrome, BMI: body mass index,
EDSS: expanded disability status scale, NT: no treatment, IFN: interferon, CO: copaxone, MX: mitoxantrone, and NA: not applicable.
aNumber of patients.
bMean ± SD (range).
cNumber of patients (percent).
dNumber of relapses in the 2 years before baseline.
Table 2: Volumes of T1 and FLAIR lesions at baseline and follow-up (median (interquartile range)).
T1 lesions (cm3) FLAIR lesions (cm3)
BL 1-YR 𝑝 valuea BL 1-YR 𝑝 valuea
CIS 0.4 (0.0–0.6) 0.3 (0.2–0.8) 0.046 1.0 (0.3–2.2) 1.3 (0.5–3.1) 0.001
RRMS 1.4 (0.5–3.7)∗,# 3.0 (0.8–6.0) 0.001 6.3 (2.6–17.5)∗,# 14.0 (6.0–24.8) 0.00002
SPMS 5.8 (2.2–9.4)∗ 6.5 (3.7–18.6) 0.041 18.4 (11.6–30.1)∗ 29.3 (24.8–40.2) 0.004
PPMS 0.8 (0.6–2.8)∗,# 2.0 (0.9–4.7) 0.004 5.3 (3.1–10.4)∗,# 9.7 (6.8–15.1) 0.0004
RRMS: relapsing-remitting MS, SPMS: secondary progressive MS, PPMS: primary progressive MS, CIS: clinically isolated syndrome, and BL: baseline.
aThe intraindividual changes in the volumes of MRI over the follow-up period, Wilcoxon signed-rank test.
∗Compared to CIS group, Mann-Whitney𝑈 test, 𝑝 < 0.01.
#Compared to SPMS, Mann-Whitney𝑈 test, 𝑝 < 0.05.
longer disease duration and were older than the patients with
RRMS or CIS (𝑝 < 0.05). The EDSS scores were lower in CIS
and RRMS than in other MS subtypes (𝑝 < 0.05), while no
differences were found between SPMS and PPMS.There were
no differences in BMI between any of the MS subtypes and
CIS (𝑝 > 0.05).
At the end of the follow-up, the EDSS score was increased
in 27% (𝑛 = 17/65) of CDMS patients: (21% RRMS, 40%
SPMS, and 25% PPMS). Two years before study entry, half
of RRMS patients were relapse-free, 12% had one relapse, and
the remaining 38% of subjects had 2–5 relapses. At the end of
the follow-up, 68% of RRMS patients were relapse-free, 15%
of patients had one relapse, and the remaining 17% of subjects
had 2–5 relapses. The majority of RRMS patients were
treated with immunomodulatory drugs (53% interferon-beta
(IFN-𝛽), 6% glatiramer acetate, and 3% mitoxantrone). At
the end of follow-up, 35% of patients were treated with IFN-
𝛽, 26% of patients with copaxone, and 3% of patients with
natalizumab.
The baseline EDSS score of CIS patients was 0 except for
two subjects having score 1. Over the two-year period, 7 out
of 15 CIS patients converted to CDMS. All converted patients
had elevated IgG index and OCBs in their CSF.
3.1.2. Volumes of T1-Weighted and FLAIR Lesions. The vol-
umes of MS plaques were determined in the 75MS and
CIS patients at the baseline and after one year (Table 2). As
expected, the baseline volumes of T1-weighted and FLAIR
lesions were lowest in the CIS group (𝑝 < 0.01). Baseline
comparison between the MS subtypes showed higher FLAIR
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Table 3: The levels of adipokines in MS subtypes and CIS over follow-up period (median (interquartile range)).
Baseline One year Two years
Adiponectin (ng/mL)
CIS
RRMS
SPMS
PPMS
4720.6 (4124.4–5407.7)
4517.3 (3380.6–6417.2)
4748.4 (3977.9–6379.9)
5618.7 (4111.5–8467.1)
5131.0 (4239.4–5880.3)
4695.7 (3452.4–7270.5)
5314.8 (4289.4–7494.9)
5855.8 (4622.6–9948.3)
5149.7 (4789.0–6812.0)
5012.7 (3222.8–7043.1)
6062.3 (4706.5–7871.2)
5278.5 (3761.6–8779.1)
Adipsin (ng ×m2/mL × kg)a
CIS
RRMS
SPMS
PPMS
63.9 (53.9–76.8)
60.3 (52.3–71.2)∗,#
68.4 (57.4–85.0)
80.8 (69.5–93.6)
66.4 (56.9–83.5)
62.4 (55.1–71.3)∗,#
70.3 (63.3–81.7)
75.9 (67.1–94.6)
66.7 (59.7–74.4)
61.5 (56.2–69.6)∗,#
74.1 (57.7–89.6)
82.5 (66.1–95.0)
Leptin (pg ×m2/mL × kg)b
CIS
RRMS
SPMS
PPMS
861.0 (269.8–1908.4)
662.4 (288.1–981.4)
711.1 (166.8–1649.7)
515.2 (182.6–1260.2)
694.9 (240.1–1238.7)
572.4 (286.7–1159.3)
420.0 (157.5–1496.2)
603.3 (203.5–1092.2)
754.5 (424.2–1346.5)
572.0 (321.4–1032.9)
953.2 (287.9–1822.7)
479.3 (255.6–776.1)
Resistin (pg/mL)
CIS
RRMS
SPMS
PPMS
2851.5 (2509.1–3280.5)
2505.2 (2085.0–2751.0)
2605.4 (2216.0–3388.0)
2392.5 (1794.9–3411.5)
2946.6 (2367.6–3093.8)
2402.1 (2064.9–2869.3)
2649.9 (2358.5–3146.4)
2371.2 (1663.5–3354.6)
2769.5 (2299.2–3072.8)
2315.9 (1946.9–2796.2)
2469.0 (2284.6–2975.3)
2445.4 (1711.1–3349.5)
aBMI-adjusted adipsin levels (ng ×m2/mL × kg).
bBMI-adjusted leptin levels (pg ×m2/mL × kg).
∗Comparison of PPMS 𝑝 < 0.01.
#Comparison of PPMS after adjusting for age 𝑝 < 0.05.
and T1 lesion volumes in SPMS than in PPMS or RRMS
(𝑝 < 0.05). Over the follow-up, the volumes of these lesions
increased in all studied groups (𝑝 < 0.05).
3.2. Levels of Adipokines in MS Subtypes during the Two-
Year Follow-Up. Correlation analyses assessing associations
of adipokines with BMI in CDMS group showed correlations
with levels of adipsin (𝑟 = 0.277, 𝑝 = 0.018) and leptin (𝑟 =
0.491, 𝑝 < 0.0001) but not with adiponectin (𝑟 = −0.132, 𝑝 =
0.267) or resistin (𝑟 = −0.071, 𝑝 = 0.551). Due to observed
correlations with adipsin and leptin, these adipokines were
adjusted by dividing their concentrations by BMI. To assess
the differences in the adipokines levels between different
MS subtypes, repeated measures of ANOVA adjusting for
age and gender were used. It appeared that over the two
years the levels of adipokines in different groups remained
stable (Table 3). The levels of BMI-adjusted adipsin in RRMS
patients were lower than those in subjects with PPMS
throughout the whole follow-up period (Table 3) (𝑝 = 0.002).
After controlling for age alone, the difference in the adipsin
levels between the groupswas still statistically significant (𝑝 =
0.037 adjusted), while after adjusting simultaneously for age
and gender only a trend toward statistical significance was
found (𝑝 = 0.057). Other adipokines levels did not differ
between the subtypes. Figure 1 illustrates the baseline distri-
bution of the adipokines levels in patients with different sub-
types. Notably, the levels of BMI-adjusted adipsin in treated
and untreated RRMS patients were decreased in comparison
to PPMS, but no differences were found between these RRMS
groups (Supplementary Figure 1 in Supplementary Mate-
rial available online at http://dx.doi.org/10.1155/2015/371734).
Likewise, the levels of adipokines were of the similar magni-
tude in converted and nonconverted patients with CIS.
The influence of gender on secretion of adipokines was
studied by comparing the baseline levels in men and women.
It appeared that in CDMS group the levels of leptin (869.6
(536.9–1504.9) versus 242.3 (152.9–441.3) pg × m2/mL ×
kg, 𝑝 < 0.001) and adiponectin (5540.9 (4197.4–8036.1)
versus 3808.0 (3178.7–5545.4) ng/mL, 𝑝 = 0.010, median
(interquartile range)) were higher in women. In CDMS, also
the age correlated with the levels of BMI-adjusted adipsin
(𝑟 = 0.491, 𝑝 < 0.001).
3.3. Association ofAdipokineswithClinical andMRIMeasures.
Association of adipokines levels with baseline EDSS score
and the volumes of FLAIR- or T1-weighted lesions as well as
the change of their volumes over the follow-up were studied
by linear regression model adjusting for age, gender, and
disease subtype. In the CDMS group, the analyses among
the adipokines showed a positive correlation between the
baseline BMI-adjusted adipsin and EDSS scores (𝑟 = 0.506,
𝑝 < 0.001), and such associations were also observed after
adjusting for age alone (𝑟 = 0.387, 𝑝 = 0.003), for age
and gender (𝑟 = 0.376, 𝑝 = 0.004), or for combination of
age, gender, and disease subtype (𝑟 = 0.280, 𝑝 = 0.036).
According to subtype analysis, inRRMSgroup the correlation
was even stronger (𝑟 = 0.542, 𝑝 = 0.002; Figure 2(a)). Similar
associations were observed after adjusting for age (𝑟 = 0.570,
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Figure 1: Scatter plot showing the baseline levels of Adiponectin (A), Resistin (B), BMI-adjusted Adipsin (C) and BMI-adjusted Leptin (D)
in MS and CIS. The bars indicate the median and interquartile range.
Table 4: Observed associations between the levels of adipsin and clinical and MRI parameters (Pearson’s correlation coefficient (𝑝 value)).
Parameters Basic model Adjusted for age Adjusted for age and gender Adjusted for age, gender, and subtype
EDSS CDMS 0.506 (<0.0001) 0.387 (0.003) 0.376 (0.004) 0.280 (0.036)
RRMS 0.542 (0.002) 0.570 (0.001) 0.569 (0.002) —
T1 lesion volume RRMS 0.410 (0.034) 0.402 (0.042) 0.407 (0.043) —
FLAIR lesion volume RRMS 0.601 (0.001) 0.596 (0.001) 0.596 (0.002) —
ΔT1 lesion volume RRMS 0.582 (0.003) 0.582 (0.004) 0.583 (0.004) —
CDMS: clinically definite MS, RRMS: relapsing-remitting MS, EDSS: expanded disability status scale, and FLAIR: fluid attenuation inversion recovery.
𝑝 = 0.001) or age and gender (𝑟 = 0.569, 𝑝 = 0.002).Over the
two years, the EDSS score increased in 27% of CDMS patients
(𝑛 = 17/65) (21%RRMS, 40% SPMS, and 25%PPMS), but the
levels of adipokines did not associate with this change.
In the CDMS group, the levels of adipokines did not
associate with the volumes of FLAIR- or T1-weighted lesions
or the change of their volumes over the follow-up (𝑝 >
0.05). However, according to subgroup analysis, in RRMS
correlations were found between the baseline levels of BMI-
adjusted adipsin and the volumes of T1-weighted (𝑟 = 0.410,
𝑝 = 0.034; Figure 2(b)) and FLAIR (𝑟 = 0.601, 𝑝 = 0.0001;
Figure 2(c)) lesions or the changes of T1 lesion volumes
over the follow-up (𝑟 = 0.582, 𝑝 = 0.003; Figure 2(d)).
After adjusting for age and gender, RRMS group still showed
positive correlations in thesemeasures indicating that age and
gender did not have an impact on these correlations (Table 4).
We next analysed whether the levels of adipokines are
associated with clinical or MRI disease activity before study
entry and over the follow-up period. Baseline clinical disease
activity was determined by the presence of at least 2 relapses
during 2 years before study entry and baseline MRI activity
by presence of at least one Gd-enhancing lesion. The disease
activity on MRI over the follow-up was assessed based on
the presence of at least one Gd-enhancing lesion or new T2
lesion. At the study entry, the presence of higher clinical
disease activity (𝑛 = 13, at least 2 relapses/2 years before
baseline) was associated with higher levels of BMI-adjusted
adipsin in comparison to patients with stable disease course
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Figure 2: Associations between baseline BMI-adjusted adipsin and EDSS score (a), the volumes of T1 lesions (b), FLAIR lesions (c), and
changes of T1 lesion volumes over the follow-up (d) in RRMS patients.
(𝑛 = 21, 0-1 relapses/2 years before baseline) (Figure 3).
However, no associations were found over the follow-up.
Regarding the MRI activity, half of the patients (18/34)
showed MRI activity according to defined criteria (presence
of Gd-enhancing lesion or new T2 lesion over the follow-up
period), but association between adipokines levels and MRI
activity was not found.
4. Discussion
Currently very little is known about the impact of adipokines
on MS. This exploratory study assessed the ability of best-
known adipokines to discriminate between MS subtypes
and their potential to depict inflammatory activity and
neurological deterioration in MS. A correlation between the
baseline levels of adipsin and EDSS scores detected in whole
MS and RRMS cohorts suggests an involvement of adipsin
in pathophysiology of MS. Such interpretation is further
supported by the correlations detected between the baseline
adipsin and the volumes of T1-weighted and FLAIR lesions as
well as the change of such lesion volumes over the follow-up
seen in RRMS group.
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Figure 3: Scatter plot showing the levels of adipsin in stable
and active RRMS patients. The bars indicate the median and
interquartile range.
Adipsin (complement factor D) is a key enzyme involved
in the activation of alternative pathway of complement
activation and is primarily secreted from adipocytes and
monocytes/macrophages in human subjects [20]. Its role
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in the pathogenesis of MS has not been studied, but the
immunohistochemical studies have demonstrated the pres-
ence of other complement components within the lesion in
normal appearing white matter (NAWM) and cortical areas
suggesting involvement of complement proteins in MS [21,
22]. Complement components of the classical and alternative
pathway including C3, C4, C5, C9, terminals complement
complex (TCC), complement receptor, and factors B, I, and
H [23–31] have been previously analysed in sera and CSF of
MS patients [23–31]. These studies have showed the positive
correlation between CSF levels of C3, C9, and TCC and EDSS
scores [30, 32, 33].
The observed association of baseline adipsin with neuro-
logical disability expressed by EDSS score in whole MS and
RRMS cohorts suggests a role of adipsin in accumulation
of neurological disability. Moreover, in RRMS at baseline
an association between the adipsin and the volumes of T1-
weighted lesions as well as their increase over the follow-
up suggests predictive potential of adipsin as a biomarker
of neurodegeneration. According to statistical analyses, age
and gender did not influence these results. The absence of
evolution of adipokines levels over the follow-up is most
likely explained by relatively stable clinical disease course in
most of our patients. However, an increase of the volumes
of T1 and FLAIR lesions seen by MRI is consistent with
worsening ofMS even during the relatively short follow-up in
this study. In parallel, the presence of higher adipsin in a sub-
group of patients withmore active RRMS (≥2 relapses/2 years
before baseline) together with a positive correlation between
the baseline adipsin and the volumes of FLAIR lesions in
whole RRMS group suggests an involvement of adipsin also
in inflammatory disease activity. Taken together, accord-
ing to these observations adipsin is a neuroinflammation-
promoting molecule that facilitates neurological deteriora-
tion and underlying neurodegeneration. It is noteworthy that
inflammation-promoting activity of alternative complement
pathway on adaptive immune responses has been recently
reported also by other investigators [34, 35]. According to
these studies, anaphylatoxins especially produced during the
activation of alternative pathway may trigger inflammation
and chemotaxis [34], although the role of complement in the
adaptive immune responses to induce the T cell activation
and proliferation has also been proposed [35].
The presence of decreased adipsin in RRMS patients in
comparison to those with PPMS is most likely related to
different pathological mechanisms in these MS subtypes.
The early phase of RRMS is characterized predominantly by
inflammatory events initiated by activation and differentia-
tion of myelin specific CD4+ T cells into Th1 and Th17 cells
and their transmigration from periphery to CNS eventually
resulting in demyelination and axonal loss [36]. During the
transition to more advanced stages like SPMS, BBB becomes
less permeable leading to diminished entry of peripheral
immune cells and their products into CNS [37]. Recent
pathologic studies have showed that progressive subtypes are
characterized by the widespread diffuse inflammation with
slowly expanding lesions, abundant cortical lesions, and lym-
phocyte infiltration and microglia activation in the NAWM
[38]. The elevated levels of adipsin in our PPMS patients
most likely reflect peripheral immune activation and do not
associate with ongoing focal CNS changes seen on MRI.
Notably, recently the other member of complement pathway,
that is, complement factor H, was found to be elevated in
sera of patients with progressive MS but not in RRMS or
healthy controls [39]. Together the available data suggest that
elevated levels of adipsin in patients with progressive MS
reflect ongoing peripheral immune activation.
Interestingly, this study revealed positive correlations
between the BMI and the levels of leptin and adipsin. These
observations support the hypothesis of close interaction
between the adipose tissue and immune system in regulation
of inflammatory responses [5]. In addition, the presence of
higher levels of leptin and adiponectin in women indicates
the presence of gender-specific association to secretion of
these adipokines. Parallel results in MS and healthy subjects
have been reported also by others [8, 40, 41].
5. Conclusions
This study showed an association of adipsin to neurological
disability and focal changes on MRI in MS thus suggesting
that dysregulation of alternate complement pathway may
have an impact on MS disease course. The data suggest
that adipsin exerts an inflammation-promoting effect and
facilitates the development of neurodegenerative changes.
Thepredictive potential of adipsin as a biomarker of neurode-
generation needs to be evaluated in further studies.
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